Tisagenlecleucel for Non-Hodgkin's Lymphoma (BIANCA Trial)

"This particular research study is no longer looking for new participants. The listing was created on February 15th, 2019 and updated for the last time on October 31st, 2022. If you are interested in other lymphoma studies, there are currently 1820 ongoing trials related to diffuse lymphoma and 18 clinical trials testing lymphodepleting chemotherapy that are actively recruiting patients."

"Lymphodepleting chemotherapy was first studied in the year 2015 at Oregon Health & Science University Doernbecher Children's Hosp.. Since then, there have been 12 completed clinical trials. Currently, 18 studies are actively recruiting patients. A large portion of these active studies are based out of New york City."

"This trial is now closed to new participants. The study was posted on February 15th, 2019 and received its last update on October 31st, 2022. However, there are currently 1820 clinical trials related to lymphoma that are actively admitting patients."

"Lymphodepleting chemotherapy is estimated to be a 2 in terms of safety. This rating comes from the fact that, while there have been Phase 2 trials testing its safety, none have looked at whether it is effective."

"Novartis Pharmaceuticals sponsored the first study on lymphodepleting chemotherapy in 2015, which involved 97 patients. After this initial research was published, Phase 2 drug approval was granted in [year]. As of today, there are 18 active clinical trials being conducted in 115 cities and 22 countries."